Voiding Dysfunction Highlights

EAU 2012 - Comparison of two different Botulinumtoxin A products (Xeomin, Botox) used for detrusor injection in patients with bladder overactivity (BO) – a prospective randomized double-blind study - Session Highlights

Published on Friday, 30 March 2012 14:37

PARIS, FRANCE (UroToday.com) - Botulinumtoxin A has proven efficacy in patients with BO of neurogenic as well as idiopathic origin refractory for antimuscarinics.

EAU 2012 - Neuro-urological practice in spinal injuries units in UK and Eire and EAU Neurogenic Lower Urinary Tract Dysfunction guidelines - Session Highlights

Published on Friday, 30 March 2012 14:36

PARIS, FRANCE (UroToday.com) - A vast majority of patients with spinal cord injury (SCI) will develop neurogenic lower urinary tract dysfunction (NLUTD).

EAU 2012 - The β3-adrenoceptor agonist Solabegron is safe and effective for improving symptoms of overactive bladder - Session Highlights

Published on Friday, 30 March 2012 14:34

PARIS, FRANCE (UroToday.com) - The phase 2 solabegron study results demonstrate it is safe, well tolerated, and effective for improving symptoms of overactive bladder.

EAU 2012 - Health-related quality of life in patients with overactive bladder - Session Highlights

Published on Friday, 30 March 2012 14:28

PARIS, FRANCE (UroToday.com) - Patients with overactive bladder (OAB) were surveyed to determine the impact of their disease on health-related quality of life (HR-QOL) in a community setting.

EAU 2012 - Effect of treatment response on the decision to escalate antimuscarinic dose in elderly subjects with overactive bladder - Session Highlights

Published on Friday, 30 March 2012 14:28

PARIS, FRANCE (UroToday.com) - The authors' objective was to evaluate treatment response in elderly subjects with overactive bladder (OAB) who did and did not choose to escalate from fesoterodine (FESO) 4 mg to FESO 8 mg, both before and after the dose escalation choice point.

EAU 2012 - Prevalence and clinical features of detrusor underactivity among the community-dwelling elderly with lower urinary tract symptoms: A comparison between men and women - Session Highlights

Published on Friday, 30 March 2012 14:26

PARIS, FRANCE (UroToday.com) - The prevalence and clinical implications of detrusor underactivity (DU) in the community-dwelling elderly population remain largely unknown, and subsequently, proper diagnosis and management of DU is challenging for physicians caring for the elderly with lower urinary tract symptoms (LUTS).

EAU 2012 - The efficacy and tolerability of fesoterodine fumarate in the treatment of overactive bladder symptoms in patients affected by multiple sclerosis: Long term follow up - Session Highlights

Published on Friday, 30 March 2012 14:25

PARIS, FRANCE (UroToday.com) - The efficacy and tolerability of fesoterodine fumarate has been already evaluated in the treatment of patients affected by symptoms of idiopathic overactive bladder (OAB) but no consistent data exist on the effects of the drug in OAB symptoms due to multiple sclerosis (MS).

EAU 2012 - Value of nerve growth factor levels in overactive bladder syndrome – alterations after botulinum toxin therapy - Session Highlights

Published on Friday, 30 March 2012 14:23

PARIS, FRANCE (UroToday.com) - In this abstract, the authors note that several studies discussing the pathology of overactive bladder suggest changes in urinary proteins.

EAU 2012 - The β3-adrenoceptor agonist Solabegron is safe and effective for improving symptoms of overactive bladder - Poster

Published on Friday, 30 March 2012 14:21

PARIS, FRANCE (UroToday.com) - Solabegron, a novel beta-3 adrenoceptor agonist with high affinity and selectivity, is in clinical development for the treatment of patients with overactive bladder.

EAU 2012 - Spontaneous contractile activity of human neurogenic bladder strips: Can we predict a correlation between clinical factors, urodynamics and histological features? - Session Highlights

Published on Friday, 30 March 2012 14:21

PARIS, FRANCE (UroToday.com) - The pathophysiology of neurogenic detrusor overactivity is incompletely understood.

Voiding Dysfunction Highlights

EAU 2012 - Comparison of two different Botulinumtoxin A products (Xeomin, Botox) used for detrusor injection in patients with bladder overactivity (BO) – a prospective randomized double-blind study - Session Highlights

EAU 2012 - Neuro-urological practice in spinal injuries units in UK and Eire and EAU Neurogenic Lower Urinary Tract Dysfunction guidelines - Session Highlights

EAU 2012 - The β3-adrenoceptor agonist Solabegron is safe and effective for improving symptoms of overactive bladder - Session Highlights

EAU 2012 - Health-related quality of life in patients with overactive bladder - Session Highlights

EAU 2012 - Effect of treatment response on the decision to escalate antimuscarinic dose in elderly subjects with overactive bladder - Session Highlights

EAU 2012 - Prevalence and clinical features of detrusor underactivity among the community-dwelling elderly with lower urinary tract symptoms: A comparison between men and women - Session Highlights

EAU 2012 - The efficacy and tolerability of fesoterodine fumarate in the treatment of overactive bladder symptoms in patients affected by multiple sclerosis: Long term follow up - Session Highlights

EAU 2012 - Value of nerve growth factor levels in overactive bladder syndrome – alterations after botulinum toxin therapy - Session Highlights

EAU 2012 - The β3-adrenoceptor agonist Solabegron is safe and effective for improving symptoms of overactive bladder - Poster

EAU 2012 - Spontaneous contractile activity of human neurogenic bladder strips: Can we predict a correlation between clinical factors, urodynamics and histological features? - Session Highlights

More Articles...

Conferences Menu

Disease Topics

Log in

Voiding Dysfunction Highlights

More Articles...

Conferences Menu

Disease Topics